Short Summary
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Detailed Summary
Dr. Falk Pharma GmbH (Petitioner) challenged the validity of U.S. Patent 11260061 before the PTAB, asserting obviousness over prior art references including Perrett and Dohil2009 under 35 U.S.C. § 103. The Board found that Petitioner showed a reasonable likelihood of prevailing on Ground 1 (Perrett). A key component of the decision involved claim construction, where the Board defined 'adsorbed onto a pharmaceutically acceptable carrier' as meaning 'adhered to or retained on a surface of a pharmaceutically acceptable carrier.' This finding allowed the Petitioner to advance arguments that the blending process in Perrett implicitly leads to the claimed adsorption limitation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Intas Pharmaceuticals, Ltd. et al.vsAtossa Therapeutics, Inc.
Intas Pharmaceuticals and Atossa Therapeutics have settled their dispute over U.S. Patent 12,071,391 and jointly moved to terminate the post‑grant review. The Board is asked to end the proceeding under 35 U.S.C. §327.
Amphenol CorporationvsCredo Technology Group Ltd.
Court decision.
RegenX Science Inc.vsNextgen Biologics, Inc.
A bankruptcy court approved a settlement between ISE Professional Testing & Consulting Services and Synogen Management Group, releasing all claims and assigning a non‑mammalian biotech patent portfolio. The agreement satisfies statutory settlement factors and includes cash payments and patent assignments.
Kubota North America Corporation et al.vsVermeer Manufacturing Company
Kubota has filed an IPR petition challenging 22 claims of Vermeer’s 9,321,386 patent covering compact tool carriers. The petition relies on foreign patents KR996 and JP705, plus U.S. patents Bares and Beltrami, to argue obviousness. Kubota also argues that discretionary denial is inappropriate.
Samsung Electronics Co., Ltd. et al.vsXiFi Networks R&D, Inc.
XiFi Networks requests an out‑of‑time Director Review to vacate the institution of eleven PTAB IPR/PGR proceedings filed by Samsung, arguing that Samsung’s inconsistent claim‑construction positions in a parallel district‑court case constitute good cause for reversal.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.